Heart medicine may reduce the risk of dangerous clots

Researchers have found a possible explanation for how sotagliflozin may protect the heart: the drug seems to make platelets less prone to forming hazardous clots. That means its benefits may extend beyond lowering blood sugar or affecting fluid levels.

Platelets are tiny blood components that help seal injuries and stop bleeding. But when they become overly active inside a blood vessel, they can help create a blockage that cuts off blood flow to the heart or brain.

A team at the University of Michigan examined human blood samples and carried out mouse experiments to see how sotagliflozin influences this process. Their work, published in the Journal of Clinical Investigation, points to a potential extra effect of the drug rather than proving a new treatment advantage in patients.

Sotagliflozin works by blocking two proteins, SGLT1 and SGLT2. These proteins help transport sugar, and drugs that target them are used to treat people with diabetes and some heart or kidney conditions.

The researchers compared sotagliflozin with empagliflozin, a medicine that mainly blocks SGLT2. That comparison helped them test whether SGLT1 blockade might account for platelet changes that would be missed if the drugs were grouped together.

In blood taken from healthy volunteers and people with type 2 diabetes, sotagliflozin lowered platelet activation. Empagliflozin had far smaller effects in the lab studies, suggesting the two drugs do not behave the same way on clot-forming cells.

For another possible blood-vessel benefit, see research into a diabetes medicine and aging blood vessels.

The team also examined clot formation after blood-vessel injury in mice. Under the experimental conditions, sotagliflozin cut clot formation by about 60%, compared with roughly 5% to 10% for the SGLT2-focused drug.

When SGLT1 was removed specifically from platelets, clotting also decreased, strengthening the argument that this protein is involved. Still, a drug that targets SGLT1 alone did not recreate the full effect, suggesting other mechanisms may also play a role.

One encouraging result was that the reduced clotting did not seem to interfere with normal bleeding control in the tests used. That matters because the ability to block harmful clots while preserving necessary clotting is a major challenge in cardiovascular treatment.

Even so, the findings do not prove that sotagliflozin carries no bleeding risk in people. Laboratory measurements and mouse injury models cannot capture every effect of a drug during long-term use or in patients taking other medications.

The study also cannot show that sotagliflozin prevents more heart attacks than empagliflozin in a direct clinical comparison. That would require research designed to measure patient outcomes, not just platelet activity.

For now, the work offers a more detailed biological explanation that deserves further study. A drug already used for heart-related protection may also affect the cells that drive clot formation, giving another clue to how its benefits arise.

If you are interested in this topic, please read articles about Plant-based diets show promise in managing type 2 diabetes and heart disease, and Mediterranean diet could protect artery health, reduce heart disease risk.

For more information, please see articles about Common artificial sweeteners linked to higher risk of heart disease, and Omega-3 fatty acids and heart health: What you need to know.

Source: University of Michigan.